SG Americas Securities LLC Has $1.25 Million Stock Position in ResMed Inc. (NYSE:RMD)

SG Americas Securities LLC decreased its position in shares of ResMed Inc. (NYSE:RMD - Free Report) by 80.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,126 shares of the medical equipment provider's stock after selling 21,591 shares during the period. SG Americas Securities LLC's holdings in ResMed were worth $1,251,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of RMD. BOK Financial Private Wealth Inc. acquired a new position in shares of ResMed in the 1st quarter valued at about $35,000. OFI Invest Asset Management acquired a new position in shares of ResMed in the 2nd quarter valued at about $32,000. Versant Capital Management Inc boosted its holdings in shares of ResMed by 196.7% in the 2nd quarter. Versant Capital Management Inc now owns 181 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 120 shares during the period. Financial Connections Group Inc. acquired a new position in shares of ResMed in the 2nd quarter valued at about $37,000. Finally, Riverview Trust Co acquired a new position in shares of ResMed in the 1st quarter valued at about $42,000. Institutional investors own 54.98% of the company's stock.

Insider Activity at ResMed

In related news, CFO Brett Sandercock sold 1,000 shares of the company's stock in a transaction that occurred on Tuesday, October 8th. The shares were sold at an average price of $233.47, for a total value of $233,470.00. Following the completion of the sale, the chief financial officer now owns 95,812 shares in the company, valued at approximately $22,369,227.64. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Brett Sandercock sold 1,000 shares of the company's stock in a transaction that occurred on Tuesday, October 8th. The shares were sold at an average price of $233.47, for a total value of $233,470.00. Following the completion of the sale, the chief financial officer now owns 95,812 shares in the company, valued at approximately $22,369,227.64. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael J. Farrell sold 14,683 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $214.25, for a total transaction of $3,145,832.75. Following the completion of the sale, the chief executive officer now owns 440,799 shares of the company's stock, valued at approximately $94,441,185.75. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 119,614 shares of company stock valued at $27,135,217 over the last ninety days. Insiders own 1.21% of the company's stock.

ResMed Price Performance

Shares of ResMed stock traded up $0.89 on Thursday, hitting $237.93. The company had a trading volume of 765,537 shares, compared to its average volume of 1,040,908. The business has a 50-day simple moving average of $235.54 and a 200-day simple moving average of $213.84. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.59 and a quick ratio of 1.69. The company has a market cap of $34.92 billion, a PE ratio of 36.55, a PEG ratio of 2.11 and a beta of 0.69. ResMed Inc. has a 52 week low of $132.24 and a 52 week high of $255.18.

ResMed (NYSE:RMD - Get Free Report) last released its earnings results on Thursday, August 1st. The medical equipment provider reported $2.08 EPS for the quarter, beating the consensus estimate of $2.03 by $0.05. ResMed had a net margin of 21.79% and a return on equity of 25.00%. The business had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.22 billion. During the same period in the prior year, the business earned $1.60 earnings per share. The business's quarterly revenue was up 6.9% on a year-over-year basis. Research analysts expect that ResMed Inc. will post 9.02 EPS for the current fiscal year.

ResMed Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 19th. Investors of record on Thursday, August 15th were paid a dividend of $0.53 per share. The ex-dividend date was Thursday, August 15th. This is a positive change from ResMed's previous quarterly dividend of $0.48. This represents a $2.12 annualized dividend and a yield of 0.89%. ResMed's dividend payout ratio is currently 32.57%.

Wall Street Analyst Weigh In

RMD has been the subject of several research reports. StockNews.com lowered shares of ResMed from a "buy" rating to a "hold" rating in a report on Friday, August 30th. Wolfe Research restated an "underperform" rating and issued a $180.00 target price on shares of ResMed in a research report on Wednesday, September 18th. Oppenheimer cut shares of ResMed from an "outperform" rating to a "market perform" rating in a research report on Tuesday, June 25th. Citigroup cut shares of ResMed from a "buy" rating to a "neutral" rating in a research report on Monday, June 24th. Finally, Royal Bank of Canada upped their target price on shares of ResMed from $206.00 to $224.00 and gave the stock a "sector perform" rating in a research report on Tuesday, October 1st. One analyst has rated the stock with a sell rating, six have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $218.18.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.